Upamostat

DRUG2 trials

Sponsors

Henry M. Jackson Foundation for the Advancement of Military Medicine, FHI Clinical

Conditions

SARS-CoV-2

Phase 2

PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19

CompletedNCT05954286

Henry M. Jackson Foundation for the Advancement of Military MedicineSARS-CoV-2

Start: 2024-01-29End: 2025-04-24Updated: 2026-04-17

PC06 - Master Protocol for Early Treatment and Post-Exposure Prophylaxis of COVID-19 Adaptive Platform Trial - PROTECT-APT 1

RecruitingPACTR202410841571933

FHI ClinicalSARS-CoV-2

Start: 2024-01-15Target: 300Updated: 2026-09-14